Instrument Inactif

Communiqués Bioblast Pharma Ltd Nasdaq

Actions

IL0011319527

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Enlivex Therapeutics : Immediate Report	29/05	PU
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering	29/05	GL
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering	28/05	GL
Enlivex Therapeutics : Report of Periodic or Interim Report	30/04	PU
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events	29/04	GL
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis	22/04	GL
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis	22/04	AQ
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis	16/04	GL
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis	11/04	GL
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis	11/04	GL
Enlivex Therapeutics : Notes to Consolidated Financial Statements - Form 6-K	29/03	PU
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method	07/02	GL
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method	07/02	AQ
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis	17/01	GL
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis	17/01	AQ
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis	20/12	GL
ENLIVEX THERAPEUTICS : CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2023 AND 2022 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2023 AND 2022 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K	09/11	PU
Enlivex Therapeutics : Purchase Agreement - Form 6-K	07/11	PU
Enlivex Therapeutics : Annual General Meeting of Shareholders - Form 6-K	02/11	PU
Enlivex Therapeutics : Annual General Meeting of Shareholders - Form 6-K	26/10/23	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Bioblast Pharma Ltd Nasdaq

Actions

IL0011319527

Communiqués

Filtres